Open Data

What is in the pricing dataset

Program name, pricing model, monthly price, prepaid terms, membership fees, dose behavior, semaglutide pricing where offered, delivery formats, state availability and the date each record was last verified.

What is in the trial dataset

Trial name, registration identifier, design, population, arms, primary endpoint, headline results and reported harms.

How to use it

Reuse is welcome with attribution. If you find an error in it, the corrections process is the fastest way to get it fixed for everyone.

Open Data: the shortest useful summary

Tirzepatide is a once-weekly injection titrated from 2.5 mg to a 15 mg ceiling in 2.5 mg steps at intervals of at least four weeks, producing roughly 15 to 21% mean weight reduction across the studied maintenance arms at 72 weeks and about 20% against semaglutide's 14% in the only head-to-head trial. It works while it is taken; the withdrawal evidence shows substantial regain after stopping. Compounded preparations cost from $133 a month and are not FDA-approved; brand product is approved and costs considerably more.

Those five facts decide most questions people arrive with. Everything else on this page is detail underneath them — which is worth reading before you spend $2,388 on a first year, but not worth confusing with the outline.

Open Data: where to go next

If you have not chosen a program, price your expected maintenance dose with the projector rather than reading advertisements. If you have, check what it charges at 10 mg against the price-by-dose table. If you are struggling with side effects, the side-effect reference covers each one with reported frequencies and the red flags that need a clinician. And if a program has refused to name its pharmacy, the verification walkthrough explains why that single answer outranks any price difference.

How every price on this site is stated

All-in monthly price: medication plus any recurring membership or platform fee, at the stated dose tier, before tax and before any prepaid-term discount. One basis, used everywhere: the animated price rail, the comparison tables, the provider pages, the calculators and these files all report the same number for the same program at the same dose. Where a program charges a membership, it is inside the figure rather than beside it — which is why our number for a program with a platform fee is higher than the one on its own homepage.

Prepaid rates, brand self-pay tiers and introductory rates are shown separately and never blended into a headline figure, because averaging them would produce a number that describes nobody.

How the disclosure score is computed

The score measures what a program publishes, not how good its care is. Every input is derivable from the dataset above, so you can recompute it and get the same number.

Current standings

A high score means a program tells you a lot before you pay. It is not a safety rating and it is not a recommendation.

Open Data: how this site is actually built

Every price table, ranking and comparison on this site is generated from a structured dataset rather than written by hand. That has one consequence worth stating plainly: rankings are computed, not chosen. We cannot quietly move a program up a table, because there is no table to edit — there is a dataset and a sort order, both published. The dataset is downloadable, and so is the formula for the disclosure score.

We currently track 44 routes to tirzepatide or semaglutide, priced at all six dose tiers, with entry pricing for compounded preparations starting at $133 per month. Every record carries the date it was last verified, because a price without a date is not a fact, it is a memory.

Open Data: what we will not do

We will not publish a price we cannot interpret. A figure advertised without the dose it applies to or the period it covers is left blank rather than estimated, and the blank is deliberate. We will not invent review counts, ratings or testimonials. We will not describe a compounded preparation as equivalent to an FDA-approved product, because FDA does not approve compounded drugs and does not review them for safety, effectiveness or quality before marketing. And we will not accept payment for placement, for position, or for the removal of a criticism.

Open Data: the disclosure score in full

The score measures what a program publishes before you pay — not the quality of its care, which we have no way to measure and will not pretend to. Its seven inputs and weights:

1. Price published at all six dose tiers — 25 points.
2. Price does not rise as the dose escalates — 20 points.
3. Dispensing pharmacy or prescriber identified by name — 15 points.
4. No separate recurring membership fee — 10 points.
5. Prepaid term and its rate published — 10 points.
6. State availability published — 10 points.
7. Delivery formats published — 10 points.

All seven are derivable from the published dataset, which means anyone can recompute the number and get the same answer. If you think the weighting is wrong, take the data and weight it differently; that is why it is published.

Open Data: how we handle conflicting sources

Where two sources give different prices for the same program, we show both, name each source and its date, and state that neither has been independently verified. Choosing one silently would produce a cleaner table and a less honest one. Those conflicts appear as callouts on the affected program pages.

Open Data: commercial relationships

Some outbound links are commercial and may earn a commission. Commissions do not influence rankings, scores or published prices. Table order is computed from the published dataset rather than assigned, so the ranking can be reproduced from the files on the data page. Where we have no outbound link for a program, the page says so and suggests searching for it directly rather than following an advertisement. See the advertising disclosure for the full statement.

Open Data: corrections

Substantive errors — a wrong price, a misstated dose, an incorrect trial result, a ranking moved by bad data — are logged publicly with the date they were fixed. A site publishing prices in a fast-moving market that never records a correction is not being careful; it is not checking. Report anything you believe is wrong through contact with the page URL and, if you have one, a source.

Open Data: what this site is not

It is not medical advice, it is not a pharmacy, and it does not sell medication. Tirzepatide is a prescription medicine, and only a licensed clinician who has reviewed your history can decide whether it is appropriate for you. Compounded preparations are not FDA-approved. If a program guarantees approval before a clinician has seen your record, that is the clearest warning sign available in this market, and no price justifies it.

Open Data: why any of this is worth stating

Health-adjacent comparison sites are structurally conflicted. They are funded by commissions from the companies they rank, which creates an incentive to rank the highest-paying option first and to describe the arrangement vaguely. The defences against that are boring and checkable: publish the dataset, publish the formula, compute the ranking rather than choosing it, disclose the commercial relationships in the same typeface as everything else, and log corrections publicly with dates.

None of that proves good faith. It does make bad faith detectable, which is the most any publisher can honestly offer. If our ranking and our published dataset ever disagree, that is a bug or a lie, and either way you can find it without our help.

Open Data: how to check us

Download providers.json and sort it yourself by twelve-month cost. The order should match our tables. Recompute the disclosure score from the criteria and weights on the data page; the numbers should match the badges. Follow a trial citation to its registration record and confirm the endpoint we quoted was the primary one. Any mismatch is a reportable error and goes in the corrections log with the date it was fixed.

Open Data: the limits of what a website can do

We can tell you what a program publishes and what it costs at each dose. We cannot tell you whether its clinicians are good, whether its shipments arrive on time, or whether tirzepatide is appropriate for you. The first two we do not measure and will not guess at; the third belongs to a licensed clinician with your medical history in front of them. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality before marketing, and no amount of comparison shopping changes that distinction.

Open Data: the numbers behind the site

We track 44 routes to tirzepatide or semaglutide, priced at all six dose tiers, with compounded entry pricing from $133 to $399 a month and a cheapest twelve-month total of about $2,388. Every figure carries a verification date. Anything older than a month should be re-checked before you act on it, including by us.